Document:

BLSM form 10QSB 04-30-2006 EX10.1

    BIO
      SOLUTIONS MANUFACTURING, INC.

    

    AMENDED
      AND RESTATED

    UNIT
      PURCHASE AGREEMENT

    (Regulation
      S)

    

    

    This
      Unit
      Purchase Agreement (“Agreement”)
      is
      amended and restated as of May 1, 2006, but is only effective as of the date
      of
      acceptance of the “Purchaser
      Signature Page”
by
      and
      between Bio Solutions Manufacturing, Inc., a New York corporation (the
“Company”),
      and
      the purchaser who executes the Purchaser Signature Page hereto (the
“Purchaser”).

    

    R E C I T A L S

    

    A. The
      Company desires to obtain funds from each Purchaser in order to provide working
      capital to and further the operations of the Company.

    

    B. In
      order
      to obtain such funds, the Company is offering up to 5,625,000 units (the
“Units”),
      each
      Unit consisting of one share (each
      a
“Share”
and
      collectively the “Shares”)
      of
      common
      stock, $.001 par value per share (the “Common
      Stock”),
      and
a
      share
      purchase warrant (each a “Warrant”
and
      collectively the “Warrants”),
      in
      the form annexed hereto as Exhibit
      A,
      to
      purchase shares of Common Stock (the “Warrant
      Shares”),
      on the
      terms and subject to the conditions set forth herein.
      The
      Shares, the Warrants, and the Warrant Shares are collectively referred to herein
      as the “Securities”.

    

    AGREEMENT

    

    It
      is
      agreed as follows:

    

    1.  PURCHASE
      AND SALE OF UNITS. 

     

    1.1  Purchase
      and Sale.
      In
      reliance upon the representations and warranties of the Company and each
      Purchaser contained herein and subject to the terms and conditions set forth
      herein, at each Closing, each Purchaser shall purchase, and the Company shall
      sell and issue to each Purchaser, the number of Units set forth on the Purchaser
      Signature Page bearing such Purchaser’s name at a purchase price of $0.40 per
      Unit (the “Purchase
      Price”).

     

    1.2  Warrants.
      On the
      Closing Date, the Company will issue and deliver the Warrants to the Purchasers.
      One Warrant will be issued for each Share issued on the Closing Date. The
      exercise price to acquire a Warrant Share upon exercise of a Warrant shall
      be
      $0.80 per Warrant Share. The Warrants shall be exercisable until three (3)
      years
      after the Closing Date.  

     

    2.  CLOSING(S).

     

    2.1  Date
      and Time.
      The
      closing of the sale of Units contemplated by this Agreement (each a
“Closing”)
      shall
      occur when the subscriber funds representing the net amount due the Company
      from
      the Purchase Price of the Offering (as defined in Section 8(c)) is transmitted
      by wire transfer or otherwise to or for the benefit of the Company. The
      consummation of the transactions contemplated herein for all Closings shall
      take
      place at the offices of Spectrum Law Group, LLP, 1900 Main Street, Suite 125,
      Irvine, California 92614, upon the satisfaction of all conditions to Closing
      set
      forth in this Agreement. All Closings shall occur on or before July 31, 2006,
      unless otherwise extended by the Company (the “Final
      Closing Date”).

     

    2.2  Deliveries
      by Purchaser.
      Each
      Purchaser shall deliver the following at such Purchaser’s Closing:

     

    2.2.1  a
      completed and executed Purchaser Signature Page.

     

    2.2.2  a
      check
      or wire transfer to the general account of the Company in the amount of the
      Purchase Price for each Unit purchased.

     

    2.3  Deliveries
      by Company.
      At each
      Closing, or as soon thereafter as practicable, the Company will deliver the
      following to each Purchaser:

     

    2.3.1  the
      certificates representing the Shares purchased by such Purchaser, with each
      such
      Share being in definitive form and registered in the name of the Purchaser,
      as
      set forth on the Purchaser Signature Page, against delivery to the Company
      by
      the Purchaser of the items set forth in paragraph 2.2 above; and

     

    2.3.2  A
      duly
      executed Warrant certificate for each Unit purchased by such Purchaser, with
      each such Warrant certificate being in definitive form and registered in the
      name of the Purchaser, as set forth on the Purchaser Signature Page, against
      delivery to the Company by the Purchaser of the items set forth in paragraph
      2.2
      above.

     

    2.4  Each
      Closing Identical.
      Each
      Closing shall be upon substantially identical terms and conditions to those
      contained herein. Each Closing may be effected at the Company’s sole election
      until all of the Units have been sold, provided that all of such Closings are
      held on or prior to the Final Closing Date.

     

    3.  REPRESENTATIONS
      AND WARRANTIES OF THE COMPANY.

     

    As
      a
      material inducement to each Purchaser to enter into this Agreement and to
      purchase the Units, the Company represents and warrants that the following
      statements are true and correct in all material respects as of the date hereof
      and will be true and correct in all material respects at Closing, except as
      expressly qualified or modified herein.

    

    3.1  Organization
      and Good Standing.
      The
      Company is a corporation duly organized, validly existing, and in good standing
      under the laws of the State of New York and has full corporate power and
      authority to enter into and perform its obligations under this Agreement, and
      to
      own its properties and to carry on its business as presently conducted and
      as proposed
      to be conducted. 

     

    3.2  Capitalization.
      The
      Company is authorized to issue 100,000,000 shares of Common Stock of which,
      as
      of January 31, 2006, 18,308,687 shares were issued and outstanding, and
      10,000,000 shares of preferred stock, no par value, of which no shares are
      issued and outstanding. All outstanding shares of Common Stock have been duly
      authorized and validly issued, and are fully paid, nonassessable, and free
      of
      any preemptive rights.

     

    3.3  Validity
      of Transactions.
      This
      Agreement, and each document executed and delivered by the Company in connection
      with the transactions contemplated by this Agreement, including this Agreement,
      have been duly authorized, executed and delivered by the Company and is each
      the
      valid and legally binding obligation of the Company, enforceable in accordance
      with its terms, except as limited by applicable bankruptcy, insolvency
      reorganization and moratorium laws and other laws affecting enforcement of
      creditor’s rights generally and by general principles of equity.

     

    3.4  Valid
      Issuance of Shares.
      The
      Shares that are being issued to each Purchaser hereunder, when issued, sold
      and
      delivered in accordance with the terms hereof for the consideration expressed
      herein, and upon exercise of the Warrants, the Warrant Shares, will be duly
      and
      validly issued, fully paid and nonassessable and free of restrictions on
      transfer, other than restrictions on transfer under this Agreement and under
      applicable federal and state securities laws, will be free of all other liens
      and adverse claims.

     

    3.5  No
      Violation.
      The
      execution, delivery and performance of this Agreement has been duly authorized
      by the Company’s Board of Directors and will not violate any law or any order of
      any court or government agency applicable to the Company, as the case may be,
      or
      the Articles of Incorporation or Bylaws of the Company. 

     

    3.6  SEC
      Reports and Financial Statements.
      

     

    3.6.1  The
      Company has delivered or made available to each Purchaser accurate and complete
      copies (excluding copies of exhibits) of each report, registration statement,
      and definitive proxy statement filed by the Company with the United States
      Securities and Exchange Commission (“SEC”)
      since
      January 1, 2004 (collectively, with all information incorporated by reference
      therein or deemed to be incorporated by reference therein, the “SEC
      Reports”). All
      statements, reports, schedules, forms and other documents required to have
      been
      filed by the Company with the SEC have been so filed on a timely basis, except
      as indicated in such SEC Reports. As of the time it was filed with the SEC
      (or,
      if amended or superseded by a filing prior to the date of this Agreement, then
      on the date of such filing): (i) each of the SEC Reports complied in all
      material respects with the applicable requirements of the Securities Act of
      1933, as amended (the “1933
      Act”),
      or
      the Securities Exchange Act of 1934, as amended (the “1934
      Act”);
      and
      (ii) none of the SEC Reports contained any untrue statement of a material fact
      or omitted to state a material fact required to be stated therein or necessary
      in order to make the statements therein, in the light of the circumstances
      under
      which they were made, not misleading.

     

    3.6.2  Except
      for the pro forma financial statements, the consolidated financial statements
      contained in the SEC Reports: (i) complied as to form in all material respects
      with the published rules and regulations of the SEC applicable thereto; (ii)
      were prepared in accordance with GAAP applied on a consistent basis throughout
      the periods covered (except as may be indicated in the notes to such financial
      statements and, in the case of unaudited statements, as permitted by Form 10-QSB
      of the SEC, and except that unaudited financial statements may not contain
      footnotes and are subject to normal and recurring year-end audit adjustments
      which will not, individually or in the aggregate, be material in amount); and
      (iii) fairly present, in all material respects, the consolidated financial
      position of the Company and its consolidated subsidiaries as of the respective
      dates thereof and the consolidated results of operations of the Company and
      its
      consolidated subsidiaries for the periods covered thereby. All adjustments
      considered necessary for a fair presentation of the financial statements have
      been included.

     

    3.7  No
      Material Adverse Change.
      Since
      January 31, 2006, except as identified and described in the SEC Reports, there
      has not been:

     

    (i) any
      change in the consolidated assets, liabilities, financial condition or operating
      results of the Company from that reflected in the financial statements included
      in the Company’s Quarterly Report on Form 10-QSB for the quarter ended January
      31, 2006, except for changes in the ordinary course of business which have
      not
      had and could not reasonably be expected to have a material adverse effect
      on
      the Company’s assets, properties, financial condition, operating results or
      business of the Company and its subsidiaries taken as a whole (as such business
      is presently conducted and as it is proposed to be conducted) (a “Material
      Adverse Effect”),
      individually or in the aggregate;

    

    (ii) any
      declaration or payment of any dividend, or any authorization or payment of
      any
      distribution, on any of the capital stock of the Company, or any redemption
      or
      repurchase of any securities of the Company;

    

    (iii) any
      material damage, destruction or loss, whether or not covered by insurance,
      to
      any assets or properties of the Company or its subsidiaries;

    

    (iv) any
      waiver, not in the ordinary course of business, by the Company or any subsidiary
      of a material right or of a material debt owed to it;

    

    (v) any
      satisfaction or discharge of any lien, claim or encumbrance or payment of any
      obligation by the Company or a subsidiary, except in the ordinary course of
      business and which has not had a Material Adverse Effect;

    

    (vi) any
      change or amendment to the Company’s Articles of Incorporation or Bylaws, or
      material change to any material contract or arrangement by which the Company
      or
      any subsidiary is bound or to which any of their respective assets or properties
      is subject;

    

    (vii) any
      material labor difficulties or labor union organizing activities with respect
      to
      employees of the Company or any subsidiary;

    

    (viii) any
      material transaction entered into by the Company or a subsidiary other than
      in
      the ordinary course of business; 

    

    (ix) the
      loss
      of the services of any key employee, or material change in the composition
      or
      duties of the senior management of the Company or any subsidiary;

    

    (x) the
      loss
      or threatened loss of any customer which has had or could reasonably be expected
      to have a Material Adverse Effect; or

    

    (xi) any
      other
      event or condition of any character that has had or could reasonably be expected
      to have a Material Adverse Effect.

    

    3.8  Securities
      Law Compliance.
      Assuming the accuracy of the representations and warranties of each Purchaser
      set forth in Section 4 of this Agreement, the offer, issue, sale and delivery
      of
      the Shares will constitute an exempted transaction under the 1933 Act, and
      registration of the Shares under the 1933 Act is not required. The Company
      shall
      make such filings as may be necessary to comply with the Federal securities
      laws, which filings will be made in a timely manner.

     

    4.  REPRESENTATIONS
      AND WARRANTIES OF EACH PURCHASER.

     

    Each
      Purchaser hereby represents, warrants and covenants with the Company as
      follows:

    

    4.1  Legal
      Power.
      Each
      Purchaser has the requisite individual, corporate, partnership, limited
      liability company, trust, or fiduciary power, as appropriate, and is authorized,
      if such Purchaser is a corporation, partnership, limited liability company,
      or
      trust, to enter into this Agreement, to purchase the Units hereunder, and to
      carry out and perform its obligations under the terms of this
      Agreement.

     

    4.2  Due
      Execution.
      This
      Agreement has been duly authorized, if such Purchaser is a corporation,
      partnership, limited liability company, trust or fiduciary, executed and
      delivered by such Purchaser, and, upon due execution and delivery by the
      Company, this Agreement will be a valid and binding agreement of such
      Purchaser.

     

    4.3  Access
      to Information.
      Each
      Purchaser represents that such Purchaser has been given full and complete access
      to the Company for the purpose of obtaining such information as such Purchaser
      or its qualified representative has reasonably requested in connection with
      the
      decision to purchase the Units. Each Purchaser represents that such Purchaser
      has received and reviewed copies of the SEC Reports. Each Purchaser represents
      that such Purchaser has been afforded the opportunity to ask questions of the
      officers of the Company regarding its business prospects and the Units, all
      as
      such Purchaser or such Purchaser’s qualified representative have found necessary
      to make an informed investment decision to purchase the Units.

     

    4.4  No
      1933 Act Registration.
      The
      Purchaser has been advised that the Securities have not been registered under
      the 1933 Act or applicable state securities laws and that the Units are being
      offered and sold pursuant to Regulation S under the 1933 Act and that the
      Company’s reliance upon Regulation S is predicated in part on the
      Purchaser’s representations as contained herein.

     

    4.5  Investment
      Intent.
      The
      Purchaser is acquiring the Units for Purchaser’s own account, not as a nominee
      or agent, for investment and not with a view to or for resale in connection
      with, any distribution or public offering thereof within the meaning of the
      1933
      Act, except pursuant to an effective registration statement under the 1933
      Act.

     

    4.6  Non
      U.S. Person.
      The
      Purchaser is not a U.S. Person (as defined in Regulation S) and is not an
      affiliate of the Company (as defined in Regulation S). At the time of the
      origination of contact concerning this Agreement, and at the date of execution
      and delivery of this Agreement, the Purchaser was outside the United States,
      its
      territories and possessions. 

     

    4.7  Resale
      Restrictions.
      The
      Purchaser:

     

    (a) will
      not,
      during the period commencing on the date of purchase and ending on the date
      one
      year after the date of purchase (the “Restricted Period”), offer or sell the
      Securities in the United States, its territories or possessions, or to a U.S.
      Person or for the account or benefit of a U.S. Person (other than distributors),
      other than in accordance with Rules 903 or 904 of Regulation S under
      the 1933 Act;

     

    (b) will,
      after the expiration of the Restricted Period, offer, sell, pledge or otherwise
      transfer the Securities only pursuant to registration under the 1933 Act or
      an
      available exemption therefrom and, in any case, in accordance with applicable
      state and foreign securities laws; and

     

    (c) will
      not
      to engage in hedging transactions with regard to the Securities.

    

    4.8  Directed
      Selling Efforts.
      Neither
      the Purchaser, its affiliates or any person acting on behalf of the Purchaser
      or
      any such affiliates has engaged, or will engage, in any Directed Selling Efforts
      (as defined in Regulation S under the 1933 Act) with respect to the
      Securities or any distribution, as that term is used in the definition of
      Distributor in Regulation S under the 1933 Act, with respect to the
      Securities.

     

    4.9  No
      Solicitation.
      Neither
      the Company nor any person acting on its behalf made to the Purchaser or any
      person acting on its behalf in the United States any statement conveying a
      purpose or intent to sell the Units to the Purchaser. The person executing
      this
      agreement on behalf of the Purchaser was outside the United States, its
      territories, and possessions at the time of such execution.

     

    4.10  No
      Market Conditioning.
      Neither
      the Purchaser, any affiliate of the Purchaser, nor any person acting on their
      behalf has undertaken or carried out any activity for the purpose of, or that
      could reasonably be expected to have the effect of, conditioning the market
      in
      the United States, its territories or possessions, for any of the
      Securities.

     

    4.11  No
      Scheme.
      The
      transactions contemplated by this Agreement:

     

    (a) have
      not
      been pre-arranged with a purchaser located in the United States, its territories
      or possessions, or who is a U.S. Person; and 

     

    (b) are
      not
      part of a plan or scheme to evade the registration provisions of the 1933
      Act.

    

    4.12  No
      Nominee.
      The
      Purchaser is purchasing the Securities for its own account for the purpose
      of
      investment and not (A) with a view to, or for sale in connection with, any
      distribution thereof, or (B) for the account or on behalf of any U.S.
      Person.

     

    4.13  No
      Groups.
      The
      Purchaser is not an entity or group that has been formed principally for the
      purpose of investing in securities not registered under the 1933
      Act.

     

    4.14  Compliance
      with Resale Provisions.
      If the
      Purchaser offers and sells the Securities during the Restricted Period, then
      it
      will do so only: (a) in accordance with the provisions of
      Regulation S; (b) pursuant to registration of the Securities under the
      1933 Act; or (c) pursuant to an available exemption from the registration
      requirements of the 1933 Act.

     

    4.15  Legend.
      The
      Purchaser understands that the Securities have not been registered under the
      1933 Act and may not be transferred or resold except pursuant to an effective
      registration statement or exemption from registration and each certificate
      representing the Securities will be endorsed with the following
      legend:

     

    THIS
      SECURITY HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF
      1933,
      AS AMENDED (THE “1933 ACT”), AND SUCH SECURITY MAY NOT BE OFFERED, SOLD, PLEDGED
      OR OTHERWISE TRANSFERRED EXCEPT (1) PURSUANT TO AN EFFECTIVE REGISTRATION
      STATEMENT UNDER SUCH ACT, (2) IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH
      RULE
      903 OR RULE 904 OF REGULATION S UNDER THE ACT, OR (3) PURSUANT TO AN
      EXEMPTION FROM REGISTRATION AS CONFIRMED IN AN OPINION OF COUNSEL SATISFACTORY
      TO THE COMPANY, AND IN EACH CASE IN ACCORDANCE WITH ANY OTHER APPLICABLE
      LAW.

    

    4.16  Stop
      Transfer.
      Purchaser agrees that the Company shall refuse to register any transfer of
      the
      Securities not made in accordance with Regulation S, pursuant to registration
      under the Act, or pursuant to an exemption from registration under the Act,
      and
      that the Company may place a stop transfer order with its registrar and stock
      transfer agent (if any) covering all certificates representing the
      Securities.

     

    4.17  Economic
      Risk.
      Purchaser can bear the economic risk of an investment in the Units, including
      the total loss of such investment.

     

    4.18  Suitability.
      Purchaser believes, in light of the information provided in this Agreement,
      the
      purchase of the Units pursuant to the terms of this agreement is an appropriate
      and suitable investment for the Purchaser.

     

    4.19  Investment
      Knowledge and Experience.
      Purchaser is experienced and knowledgeable in financial and business matters,
      capable of evaluating the merits and risks of purchasing the securities offered
      herein by the Company.

     

    4.20  Indemnification.
      Purchaser under takes and agrees to indemnify and hold harmless the Company
      and
      its directors, officers, servants, employees and agents from and against all
      claims, liabilities, losses, damages, costs and expenses of every kind and
      nature arising directly or indirectly from inaccuracy of any of the Purchaser’s
      representations and warranties contained in this Agreement or from the failure
      of Purchaser to take any action required of the Purchaser pursuant to this
      Agreement.

     

    4.21  Information.
      Purchaser has had the opportunity to ask questions and request information
      from
      the Company and to receive such information and answers from the Company, or
      officer, agent and or representative of the Company, concerning the terms and
      conditions of the investment and the general and overall business affairs of
      the
      Company. Purchaser has further obtained all such additional information
      necessary to verify such received information. Purchaser has received such
      additional information concerning the Company that the Purchaser considers
      necessary or advisable in order to form a decision concerning an investment
      in
      the Company.

     

    4.22  Subscription
      Acceptance.
      Purchaser understands
      that the Company will notify the Purchaser whether the offered Agreement has
      been accepted, in whole or in part, or rejected, in whole or in part. Unless
      rejected within ten (10) days of its receipt or on the day of the final date
      of
      the Offering, whichever comes later, by the Company, the Agreement shall be
      deemed to be accepted. If this Agreement is rejected by the Company, all funds
      tendered by the Purchaser will be returned, without interest or deduction.
      It is
      understood that the Company will have the sole discretion to determine which
      of
      the Agreements should be accepted or rejected, if any, and whether any of such
      Agreements should be accepted or rejected in whole or in part.

     

    4.23  Non-Contravention.
      The
      purchase of the Units by the Purchaser does not contravene any of the applicable
      securities legislation in the jurisdiction in which Purchaser resides and does
      not trigger: (i) any obligation to prepare and file a prospectus or similar
      document or any other report with respect to the purchase, or (ii) any
      registration requirement or other securities compliance obligation on the part
      of the Company.

     

    5.  COVENANTS
      OF THE COMPANY.

     

    5.1  Use
      of
      Proceeds.
      The
      Company intends to employ the proceeds from the purchase and sale of the Units
      for the purposes set forth on Schedule
      5.1
      hereto.
      Except as set forth on Schedule
      5.1,
      the
      proceeds from the purchase and sale of the Units may not and will not be used
      for accrued and unpaid officer and director salaries, payment of financing
      related debt, redemption of outstanding notes or equity instruments of the
      Company, litigation related expenses or settlements, brokerage fees, nor
      non-trade obligations outstanding on a Closing Date. Pending the Company’s use
      of the proceeds from the purchase and sale of the Units, the Company intends
      to
      invest the funds in government securities and insured, short-term,
      interest-bearing investments of varying maturities. Schedule
      5.1 represents
      the Company’s best estimate of the allocation of the proceeds from the purchase
      and sale of the Units. Future events, including the problems, delays, expenses,
      and complications frequently encountered by development stage companies such
      as
      the Company, as well as changes in economic, regulatory, or competitive
      conditions, changes in the Company’s planned business (and its success or
      failure), and changes in the Company’s product development activities, may
      require that it reallocate funds. It is possible that that the estimates in
      Schedule
      5.1 will
      prove inaccurate, that the Company’s efforts to introduce its products and
      services will require considerable additional expenditures, or that unforeseen
      events will cause the Company to expend more funds than it currently
      expects.

     

    5.2  Business
      Combination with Bioremediation Services, Inc.
      Upon
the
      closing
      of the sale of all 5,625,000 Units, the Company shall use commercially
      reasonable efforts to acquire and/or merge with Bioremediation Services, Inc.,
      a
      Mississippi corporation, on terms reasonable acceptable to the Company, the
      Purchasers, and Bioremediation Services, Inc. The Company agrees to use
      commercially reasonable efforts to commence negotiations with Bioremediation
      Services, Inc. as soon as reasonably practicable.

     

    6.  REGISTRATION.

     

    6.1  Definitions.
      As used
      in this Section 6, the following terms shall have the following
      meanings:

     

    

    6.1.1  Exchange
      Act:
      The
      Securities Exchange Act of 1934, as amended, and the rules and regulations
      of
      the SEC promulgated thereunder.

     

    6.1.2  Losses:
      See
      Section 6.6 hereof.

     

    6.1.3  Prospectus:
      The
      prospectus included in any Registration Statement (including, without
      limitation, a prospectus that discloses information previously omitted from
      a
      prospectus filed as part of an effective registration statement in reliance
      upon
      Securities Act Rule 430A), as amended or supplemented by any prospectus
      supplement, with respect to the terms of the offering of any portion of the
      Registrable Securities covered by such Registration Statement and all other
      amendments and supplements to the prospectus, including post-effective
      amendments, and all material incorporated by reference or deemed to be
      incorporated by reference in such prospectus.

     

    6.1.4  Registration
      Expenses:
      All
      reasonable expenses incurred by the Company in complying with Sections 6.3
      and
      6.4 hereof, including, without limitation, all registration and filing fees,
      printing expenses, fees and disbursements of counsel for the Company,
      accountants’ expenses (including, without limitation, any special audits or
“comfort” letters incidental to or required by any such registration), any fees
      or disbursements of underwriters customarily paid by issuers or sellers of
      securities (but excluding underwriting discounts and commissions) and blue
      sky
      fees and expenses in all states reasonably designated by the holders of
      Registrable Securities.

     

    6.1.5  Registrable
      Securities:
      The
      Shares, the Prepayment Shares, the Warrant Shares, and any Common Stock issued
      or issuable in respect of the Shares or Warrant Shares pursuant to any stock
      split, stock dividend, recapitalization, or similar event.

     

    6.1.6  Registration
      Statement:
      Any
      registration statement of the Company which covers any of the Registrable
      Securities pursuant to the provisions of this Agreement, including the
      Prospectus, amendments and supplements to such registration statement, including
      post-effective amendments, all exhibits and all material incorporated by
      reference or deemed to be incorporated by reference in such registration
      statement.

     

    6.1.7  Rule
      144:
      Rule 144
      under the Securities Act, as such Rule may be amended from time to time, or
      any
      similar rule or regulation hereafter adopted by the SEC (excluding Rule
      144A).

     

    6.1.8  SEC:
      The
      Securities and Exchange Commission.

     

    6.1.9  Securities
      Act:
      The
      Securities Act of 1933, as amended, and the rules and regulations promulgated
      by
      the SEC thereunder.

     

    6.1.10  Underwritten
      registration or underwritten offering:
      A
      registration in which securities of the Company are sold to an underwriter
      for
      reoffering to the public.

     

    6.2  Securities
      Subject to the Registration Rights.
      The
      securities entitled to the benefits of the Registration Rights set forth in
      this
      Section 6 are the Registrable Securities.

     

    6.3  Registration
      Rights.
      The
      Company shall file with the SEC a Registration Statement (on Form SB-2 or such
      other form that it is eligible to use) in order to register the Registrable
      Securities for resale and distribution under the Securities Act within the
      earlier of (a) thirty days after the Final Closing Date and (b) ninety
      (90) days
      after
      the closing
      of the sale of at least 2,500,000
      Units
      under this Agreement (the
      “Filing
      Date”)
      and
      use its best efforts to cause it to be declared effective. The Registrable
      Securities shall be reserved and set aside exclusively for the benefit of each
      Purchaser and Warrant holder, pro rata,
      and not
      issued, employed or reserved for anyone other than each such Purchaser and
      Warrant holder. The Registration Statement will immediately be amended or
      additional registration statements will be immediately filed by the Company
      as
      necessary to register additional shares of Common Stock to allow the public
      resale of all Common Stock included in and issuable by virtue of the Registrable
      Securities. The Company will use commercially reasonable efforts to respond
      to
      any oral or written comments received from the SEC relating to the Registration
      Statement within
      ten (10) business days after receipt of such comments from the SEC.  

     

    6.4  Intentionally
      Omitted.
      

     

    6.5  Expenses
      and Procedures.

     

    6.5.1  Expenses
      of Registration.
      All
      Registration Expenses (exclusive of underwriting discounts and commissions)
      shall be borne by the Company. Each holder of Registrable Securities shall
      bear
      all underwriting discounts, selling commissions, sales concessions and similar
      expenses applicable to the sale of the Registrable Securities sold by such
      holder.

     

    6.5.2  Registration
      Procedures.
      The
      Company will keep the holders of Registrable Securities advised as to the
      initiation of registration, qualification and compliance and as to the
      completion thereof. At its expense, the Company will furnish such number of
      Prospectuses and other documents incident thereto as the holders or underwriters
      from time to time may reasonably request.

     

    6.5.3  Information.
      The
      Company may require each seller of Registrable Securities as to which any
      registration is being effected to furnish such information regarding the
      distribution of such Registrable Securities as the Company may from time to
      time
      reasonably request and the Company may exclude from such registration the
      Registrable Securities of any seller who unreasonably fails to furnish such
      information after receiving such request.

     

    6.5.4  Delay
      or Suspension.
      Notwithstanding anything herein to the contrary, the Company may, at any time,
      suspend the effectiveness of any Registration Statement for a period of up
      to 60
      consecutive days or 90 days in the aggregate in any calendar year, as
      appropriate (a “Suspension
      Period”),
      by
      giving notice to each holder of Registrable Securities to be included in the
      Registration Statement, if the Company shall have determined, after consultation
      with its counsel, that the Company is required to disclose any material
      corporate development which the Company determines could reasonably be expected
      to have a material effect on the Company. Each holder of Registrable Securities
      agrees by acquisition of such Registrable Securities that, upon receipt of
      any
      notice from the Company of a Suspension Period, such holder shall forthwith
      discontinue disposition of such Registrable Securities covered by such
      Registration Statement or Prospectus until such holder (i) is advised in
      writing by the Company that the use of the applicable Prospectus may be resumed,
      (ii) has received copies of a supplemental or amended prospectus, if
      applicable, and (iii) has received copies of any additional or supplemental
      filings which are incorporated or deemed to be incorporated by reference in
      such
      Prospectus. The Company shall prepare, file and furnish to each holder of
      Registrable Securities immediately upon the expiration of any Suspension Period,
      appropriate supplements or amendments, if applicable, to the Prospectus and
      appropriate documents, if applicable, incorporated by reference in the
      Registration Statement. The Company agrees to use its best efforts to cause
      any
      Suspension Period to be terminated as promptly as possible.

     

    6.5.5  Blue
      Sky.
      The
      Company will, as expeditiously as possible, use its best efforts to register
      or
      qualify the Registrable Securities covered by a Registration Statement under
      the
      securities or blue sky laws of such jurisdictions as the Company deems
      appropriate or, in the case of an underwritten public offering, the managing
      underwriter shall reasonably request, provided that the Company shall not be
      required in connection therewith or as a condition thereto to qualify to do
      business in any jurisdiction where it is not so qualified or to take any action
      which would subject it to taxation or service of process in any jurisdiction
      where it is not otherwise subject to such taxation or service of
      process.

     

    6.5.6  Notification
      of Material Events.
      The
      Company will, as expeditiously as possible, immediately notify each holder
      of
      Registrable Securities under a Registration Statement, at any time when a
      prospectus relating thereto is required to be delivered under the Securities
      Act, of the happening of any event as a result of which the Prospectus contained
      in such Registration Statement, as then in effect, includes an untrue statement
      of a material fact or omits to state any material fact required to be stated
      therein or necessary to make the statements therein not misleading in the light
      of the circumstances then existing and, as expeditiously as possible, amend
      or
      supplement such Prospectus to eliminate the untrue statement or the
      omission.

     

    6.6  Indemnification.

     

    6.6.1  Indemnification
      by Company.
      The
      Company shall, without limitation as to time, indemnify and hold harmless,
      to
      the full extent permitted by law, each holder of Registrable Securities, its
      officers, directors, agents and employees, each person who controls such holder
      (within the meaning of Section 15 of the Securities Act or Section 20 of the
      Exchange Act), and the officers, directors, agents or employees of any such
      controlling person, from and against all losses, claims, damages, liabilities,
      costs (including, without limitation, all reasonable attorneys’ fees) and
      expenses (collectively “Losses”),
      as
      incurred, arising out of or based upon any untrue statement or alleged untrue
      statement of a material fact contained in any Registration Statement, Prospectus
      or preliminary prospectus or any amendment or supplement thereto, or arising
      out
      of or based upon any omission or alleged omission of a material fact required
      to
      be stated therein or necessary to make the statements therein in light of the
      circumstances under which they were made (in the case of any Prospectus) not
      misleading, except insofar as the same are based solely upon information
      furnished to the Company by such holder for use therein; provided, however,
      that
      the Company shall not be liable in any such case to the extent that any such
      Loss arises out of or is based upon an untrue statement or alleged untrue
      statement or omission made in any preliminary prospectus or Prospectus if (i)
      such holder failed to send or deliver a copy of the Prospectus or Prospectus
      supplement with or prior to the delivery of written confirmation of the sale
      of
      Registrable Securities and (ii) the Prospectus or Prospectus supplement would
      have corrected such untrue statement or omission. If requested, the Company
      shall also indemnify underwriters, selling brokers, dealer managers and similar
      securities industry professionals participating in the distribution, their
      officers, directors, agents and employees and each person who controls such
      persons (within the meaning of Section 15 of the Securities Act or Section
      20 of
      the Exchange Act) to the same extent as provided above with respect to the
      indemnification of the holders of Registrable Securities.

     

    6.6.2  Indemnification
      by Holder of Registrable Securities.
      In
      connection with any Registration Statement in which a holder of Registrable
      Securities is participating, such holder of Registrable Securities shall furnish
      to the Company in writing such information as the Company may reasonably request
      for use in connection with any Registration Statement or Prospectus. Such holder
      hereby agrees to indemnify and hold harmless, to the full extent permitted
      by
      law, the Company, and its officers, directors, agents and employees, each person
      who controls the Company (within the meaning of Section 15 of the Securities
      Act
      or Section 20 of the Exchange Act), and the officers, directors, agents or
      employees of any such controlling person, from and against all losses, as
      incurred, arising out of or based upon any untrue statements or alleged untrue
      statement of material fact contained in any Registration Statement, Prospectus
      or preliminary prospectus, or arising out of or based upon any omission of
      a
      material fact required to be stated therein or necessary to make the statements
      therein in light of the circumstances under which they were made (in the case
      of
      any Prospectus) not misleading, to the extent, but only to the extent, that
      such
      untrue statement or omission is contained in any information so furnished in
      writing by such holder to the Company for use in such Registration Statement,
      Prospectus or preliminary prospectus. The Company shall be entitled to receive
      indemnities from accountants, underwriters, selling brokers, dealer managers
      and
      similar securities industry professionals participating in the distribution
      to
      the same extent as provided above with respect to information so furnished
      by
      such persons specifically for inclusion in any Registration Statement,
      Prospectus or preliminary prospectus, provided, that the failure of the Company
      to obtain any such indemnity shall not relieve the Company of any of its
      obligations hereunder. Notwithstanding any provision of this Section 6.6 to
      the contrary, the liability of a holder of Registrable Securities under this
      Section 6.6 shall not exceed the purchase price received by such holder for
      the Registrable Securities sold pursuant to a Registration Statement or
      Prospectus.

     

    6.6.3  Conduct
      of Indemnification Proceedings.
      If any
      action or proceeding (including any governmental investigation or inquiry)
      shall
      be brought or any claim shall be asserted against any person entitled to
      indemnity hereunder (an “indemnified
      party”),
      such
      indemnified party shall promptly notify the party from which such indemnity
      is
      sought (the “indemnifying
      party”)
      in
      writing, and the indemnifying party shall assume the defense thereof, including
      the employment of counsel reasonably satisfactory to the indemnified party
      and
      the payment of all fees and expenses incurred in connection with the defense
      thereof. All such fees and expenses (including any fees and expenses incurred
      in
      connection with investigation or preparing to defend such action or proceeding)
      shall be paid to the indemnified party, as incurred, within 20 days of written
      notice thereof to the indemnifying party; provided, however, that if, in
      accordance with this Section 6.6, the indemnifying party is not liable to the
      indemnified party, such fees and expenses shall be returned promptly to the
      indemnifying party. Any such indemnified party shall have the right to employ
      separate counsel in any such action, claim or proceeding and to participate
      in
      the defense thereof, but the fees and expenses of such counsel shall be the
      expense of such indemnified party unless (a) the indemnifying party has
      agreed to pay such fees and expenses, (b) the indemnifying party shall have
      failed promptly to assume the defense of such action, claim or proceeding and
      to
      employ counsel reasonably satisfactory to the indemnified party in any such
      action, claim or proceeding, or (c) the named parties to any such action,
      claim or proceeding (including any impleaded parties) include both such
      indemnified party and the indemnifying party, and such indemnified party shall
      have been advised by counsel that there may be one or more legal defenses
      available to it which are different from or additional to those available to
      the
      indemnifying party (in which case, if such indemnified party notifies the
      indemnifying party in writing that it elects to employ separate counsel at
      the
      expense of the indemnifying party, the indemnifying party shall not have the
      right to assume the defense of such action, claim or proceeding on behalf of
      such indemnified party, it being understood, however, that the indemnifying
      party shall not, in connection with any one such action, claim or proceeding
      or
      separate but substantially similar or related actions, claims or proceedings
      in
      the same jurisdiction arising out of the same general allegations or
      circumstances, be liable for the reasonable fees and expenses of more than
      one
      separate firm of attorneys (together with appropriate local counsel) at any
      time
      for all such indemnified parties, unless in the opinion of counsel for such
      indemnified party a conflict of interest may exist between such indemnified
      party and any other of such indemnified parties with respect to such action,
      claim or proceeding, in which event the indemnifying party shall be obligated
      to
      pay the fees and expenses of such additional counsel or counsels). No
      indemnifying party will consent to entry of any judgment or enter into any
      settlement which does not include as an unconditional term thereof the release
      of such indemnified party from all liability in respect to such claim or
      litigation without the written consent (which consent will not be unreasonably
      withheld) of the indemnified party. No indemnified party shall consent to entry
      of any judgment or enter into any settlement without the written consent (which
      consent will not be unreasonably withheld) of the indemnifying party from which
      indemnify or contribution is sought.

     

    6.6.4  Contribution.
      If the
      indemnification provided for in this Section 6.6 is unavailable to an
      indemnified party under Section 6.6.1 or 6.6.2 hereof (other than by reason
      of
      exceptions provided in those Sections) in respect of any Losses, then each
      applicable indemnifying party in lieu of indemnifying such indemnified party
      shall contribute to the amount paid or payable by such indemnified party as
      a
      result of such Losses, in such proportion as is appropriate to reflect the
      relative fault of the indemnifying party and indemnified party in connection
      with the actions, statements or omissions which resulted in such Losses as
      well
      as any other relevant equitable considerations. The relative fault of such
      indemnifying party and the indemnified party shall be determined by reference
      to, among other things, whether any action in question, including any untrue
      statement or alleged untrue statement of a material fact or omission or alleged
      omission of a material fact, has been taken or made by, or relates to
      information supplied by, such indemnifying party or indemnified party, and
      the
      parties’ relative intent, knowledge, access to information and opportunity to
      correct or prevent such action, statement or omission. The amount paid or
      payable by a party as a result of any Losses shall be deemed to include, subject
      to the limitations set forth in Section 6.6.3, any legal or other fees or
      expenses reasonably incurred by such party in connection with any action, suit,
      claim, investigation or proceeding.

     

    The
      parties hereto agree that it would not be just and equitable if contribution
      pursuant to this Section 6.6.4 were determined by pro rata allocation or by
      any
      other method of allocation which does not take into account the equitable
      considerations referred to in the immediately preceding paragraph. No person
      guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
      of
      the Securities Act) shall be entitled to contribution from any person who was
      not guilty of such fraudulent misrepresentation.

    

    6.7  Rule
      144.
      The
      Company shall file the reports required to be filed by it under the Securities
      Act and the Exchange Act and the rules and regulations adopted by the SEC
      thereunder, and will take such further action as any holder of Registrable
      Securities may reasonably request, all to the extent required from time to
      time
      to enable such holder to sell Registrable Securities without registration under
      the Securities Act within the limitation of the exemption provided by Rule
      144
      or Rule 144A. Upon the request of any holder of Registrable Securities, the
      Company shall deliver to such holder a written statement as to whether the
      Company has complied with such requirements. Notwithstanding the foregoing,
      nothing in this Section 6.7 shall be deemed to require the Company to register
      any of its securities under any section of the Exchange Act.

     

    6.8  Underwritten
      Registrations.
      No
      holder of Registrable Securities may participate in any underwritten
      registration hereunder unless such person (i) agrees to sell such holder’s
      Registrable Securities on the basis provided in any underwriting arrangements
      approved by the persons entitled hereunder to approve such arrangements, and
      (ii) completes and executes all
      questionnaires, powers of attorney, indemnities, underwriting agreements and
      other documents required under the terms of such underwriting
      arrangements.

     

    

    

    7.  BROKER/LEGAL
      FEES.

     

    7.1  Investment
      Banker’s Commission.
      The
      Company on the one hand, and each Purchaser (for himself only) on the other
      hand, agrees to indemnify the other against and hold the other harmless from
      any
      and all liabilities to any persons claiming brokerage commissions or similar
      fees other than the entity identified on Schedule
      7
      hereto,
      (“Investment
      Banker”)
      on
      account of services purported to have been rendered on behalf of the
      indemnifying party in connection with this Agreement or the transactions
      contemplated hereby and arising out of such party’s actions. Anything in this
      Agreement to the contrary notwithstanding, each Purchaser is providing
      indemnification only for such Purchaser’s own actions and not for any action of
      any other Purchaser. Each Purchaser’s liability hereunder is several and not
      joint. The Company agrees that it will pay the Investment Banker the fees set
      forth on Schedule
      7
      hereto
      (“Investment
      Banker’s Fees”).
      The
      Company represents that there are no other parties entitled to receive fees,
      commissions, or similar payments in connection with the offering described
      in
      this Agreement except the Investment Banker.

     

    7.2  Legal
      Fees.
      The
      Company shall pay to Spectrum Law Group, LLP, the Company’s legal fees and costs
      due and owing to Spectrum Law Group, LLP as of the Closing Date and a deposit
      of
      $25,000 (“Company’s
      Legal Fees”)
      as
      reimbursement for services rendered, and a deposit for future services to be
      rendered, to the Company, including those services rendered in connection with
      this Agreement, the offering of the Units (the “Offering”),
      and
      those services to be rendered in connection with the Registration Statement.
      The
      Company’s Legal Fees will be payable on the initial Closing Date out of funds
      held pursuant to the Escrow Agreement.

     

    8.  MISCELLANEOUS.

     

    8.1  Indemnification.
      Each
      Purchaser agrees to defend, indemnify and hold the Company harmless against
      any
      liability, costs or expenses arising as a result of any dissemination of any
      of
      the Shares by such Purchaser in violation of the 1933 Act or applicable state
      securities law.

     

    8.2  Governing
      Law.
      This
      Agreement shall be governed by and construed under the laws of the State of
      New
      York.

     

    8.3  Successors
      and Assigns.
      Except
      as otherwise expressly provided herein, the provisions hereof shall inure to
      the
      benefit of, and be binding upon, the successors, assigns, heirs, executors,
      and
      administrators of the parties hereto.

     

    8.4  Entire
      Agreement.
      This
      Agreement and the Exhibits hereto and thereto, and the other documents delivered
      pursuant hereto and thereto, constitute the full and entire understanding and
      agreement among the parties with regard to the subjects hereof and no
      party shall
      be
      liable or bound to any other party in any manner by any representations,
      warranties, covenants, or agreements except as specifically set forth herein
      or
      therein. Nothing in this Agreement, express or implied, is intended to confer
      upon any party, other than the parties hereto and their respective successors
      and assigns, any rights, remedies, obligations, or liabilities under or by
      reason of this Agreement, except as expressly provided herein.

     

    8.5  Severability.
      In case
      any provision of this Agreement shall be invalid, illegal, or unenforceable,
      it
      shall to the extent practicable, be modified so as to make it valid, legal
      and
      enforceable and to retain as nearly as practicable the intent of the parties,
      and the validity, legality, and enforceability of the remaining provisions
      shall
      not in any way be affected or impaired thereby.

     

    8.6  Amendment
      and Waiver.
      Except
      as otherwise provided herein, any term of this Agreement may be amended, and
      the
      observance of any term of this Agreement may be waived (either generally or
      in a
      particular instance, either retroactively or prospectively, and either for
      a
      specified period of time or indefinitely), with the written consent of the
      Company and the Purchasers, or, to the extent such amendment affects only one
      Purchaser, by the Company and such Purchaser. Any amendment or waiver effected
      in accordance with this Section shall be binding upon each future holder of
      any
      security purchased under this Agreement (including securities into which such
      securities have been converted) and the Company.

     

    8.7  Notices.
      All
      notices and other communications required or permitted hereunder shall be in
      writing and shall be effective when delivered personally, or sent by telex
      or
      telecopier (with receipt confirmed), provided that a copy is mailed by
      registered mail, return receipt requested, or when received by the addressee,
      if
      sent by Express Mail, Federal Express or other express delivery service (receipt
      requested) in each case to the appropriate address set forth below:

     

    If
      to the
      Company: Bio
      Solutions Manufacturing, Inc.

    1161
      James Street

    Hattiesburg,
      Mississippi 39401          

    If
      to the
      Purchaser: At
      the
      address set forth on the Purchaser’s Signature Page

    

    8.8  Faxes
      and Counterparts.
      This
      Agreement may be executed in one or more counterparts. Delivery of an executed
      counterpart of the Agreement or any exhibit attached hereto by facsimile
      transmission shall be equally as effective as delivery of an executed hard
      copy
      of the same. Any party delivering an executed counterpart of this Agreement
      or
      any exhibit attached hereto by facsimile transmission shall also deliver an
      executed hard copy of the same, but the failure by such party to deliver such
      executed hard copy shall not affect the validity, enforceability or binding
      nature effect of this Agreement or such exhibit.

     

    8.9  Titles
      and Subtitles.
      The
      titles of the paragraphs and subparagraphs of this Agreement are for convenience
      of reference only and are not to be considered in construing this
      Agreement.

     

    [REMAINDER
      OF PAGE INTENTIONALLY LEFT BLANK]

    
      
        --

         

      

      
         

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, the parties have executed this Agreement as of the date set
      forth on the Purchase Signature Page hereto. 

    

    PURCHASER

    

    (By
      Counterpart Form - SP Pages)

    

    

    COMPANY

    

    BIO
      SOLUTIONS MANUFACTURING, INC.

    

    

    

    By:       

    David
      S.
      Bennett, 

    President

    

    
      
        
          --

        

         

      

      
         

        
          

        

      

      
         

        
        

      

    

    PURCHASER
      SIGNATURE PAGE

    

    The
      undersigned Purchaser has read the Unit Purchase Agreement amended and restated
      as of May 1, 2006 and acknowledges that execution of this Purchaser Signature
      Page shall constitute the undersigned’s execution of such
      agreement.

    

    I
      hereby
      subscribe for an aggregate of _________ Units at $0.40 per Unit and hereby
      deliver good funds with respect to this subscription for the Units.

    

    

    I
      am a
      resident of the country of __________________. 

    

     

    Please
      print above the exact name(s) in which the Units/Shares are to be
      held

    

    

    My
      address is:            

    

     

    

     

    

    
      
        SP-

         

      

      
         

        
          

        

      

      
         

      

    

    

    Executed
      this _____ day of [June]/[July], 2006 at ____________________,
      ________________.

    

    SIGNATURES

    

    INDIVIDUAL

    

    

    
      	
               

               

               

              Signature
                (Individual)

            	
               

              Name

               

              Street
                address

            
	 	 
	 	
              Address
                to Which Correspondence Should be
                Directed

            

    

    

    
      	
               

              Signature
                (All record holders should sign)

            	
               

              City,
                State and Zip Code

            

    

    

    
      	
               

              Name(s)
                Typed or Printed

            	
               

              Tax
                Identification or Social Security Number

              (
                )     

              Telephone
                Number

            

    

    

    
      	
               

              Name(s)
                Typed or Printed (All recorded holders should sign)

            	 

    

    

    

     

    
      
        SP-

         

      

      
         

        
          

        

      

      
         

      

    

    CORPORATION,
      PARTNERSHIP, TRUST ENTITY OR OTHER

    

    

    
      	 	
              Address
                to Which Correspondence Should be
                Directed:

            

    

    

    
      	
               

              Type
                of Entity (i.e., corporation, partnership, etc.)

            	
               

              Street
                Address

            

    

     

    
      	
               

              By:
                      

              *Signature

            	
               

               

              Tax
                Identification or Social Security Number

            
	 	 

    

    

    
      	
               

              State
                of Formation of Entity

            	
               

              City,
                State and Zip Code

            

    

    

    
      	
               

              Name
                Typed or Printed

            	 

    

    

    
      	
              Its:
                      

              Title

            	
              (
                )     

              Telephone
                Number

            

    

    

    *If
      Units
      are being subscribed for by an entity, the Certificate of Signatory must also
      be
      completed.

    

    
      
        SP-

         

      

      
         

        
          

        

      

      
         

      

    

    CERTIFICATE
      OF SIGNATORY

    

    To
      be
      completed if Units are being subscribed for by an entity.

    

    

    I,__________________________________,
      am the ___________________________ of 

    

    (the
      “Entity”).

    

    I
      certify
      that I am empowered and duly authorized by the Entity to execute and carry
      out
      the terms of the Unit Purchase Agreement and to purchase and hold the shares
      of
      Common Stock and the Warrants. The Unit Purchase Agreement has been duly and
      validly executed on behalf of the Entity and constitutes a legal and binding
      obligation of the Entity.

    

    IN
      WITNESS WHEREOF, I have hereto set my hand this ______ day of
      [June]/[July], 2006.

    

    

    
      	 	
              Signature

            

    

    

    

    

    
      
        SP-

         

      

      
         

        
          

        

      

      
         

      

    

    

    ACCEPTANCE

    

    

    AGREED
      AND ACCEPTED:

    

    BIO
      SOLUTIONS MANUFACTURING, INC.

    

    

    

    By:   

    David
      S.
      Bennett,

    President
      

    

    Date:
      [June]/[July] __, 2006

    

    

    
      
        
          SP-

        

         

      

      
         

        
          

        

      

      
         

        
          

        

      

    

    

    
      
        
          

        

         

      

      
         

        
          

        

      

      
         

        
          

        

      

    

    SCHEDULE
      5.1

    

    USE
      OF PROCEEDS

    

    $157,500 Investment
      Banker Fee

    $10,000 Investment
      Banker Expense Reimbursement

    $25,000 Legal
      Fees

    $2,057,500 Working
      capital and general corporate expenses

    

    

    
      
        
          Schedule
            5.1

        

         

      

      
         

        
          

        

      

      
         

        
          

        

      

    

    SCHEDULE
      7

    

    

    INVESTMENT
      BANKER: T
&
T
      Vermögensverwaltungs AG 

    Bahnhofstrasse
      73

    8001
      Zurich

     

    Cash
      Fee.
      The
      Company agrees that it will pay the Investment Banker, on each Closing Date,
      a
      fee of seven percent (7%) of the Purchase Price (“Investment
      Banker’s Cash Fee”).
      The
      Company represents that there are no other parties entitled to receive fees,
      commissions, or similar payments in connection with the Offering except the
      Investment Banker.

     

    Investment
      Banker’s Shares.
      On the
      Closing Date after
      the
closing
      of the sale of at least 2,500,000 Units, the Company will issue to the
      Investment Banker 250,000 shares of the Company’s Common Stock, and on the
      Closing Date after
      the
closing
      of the sale of all 5,625,000 Units, the Company will issue to the Investment
      Banker an additional 250,000 shares of the Company’s Common Stock (collectively,
      the “Investment
      Banker’s Shares”).

     

    Expense
      Reimbursement.
      On the
      initial Closing Date, the Investment Banker will also be paid ten thousand
      dollars ($10,000) as reimbursement of Company’s Legal Fees advanced by the
      Investment Banker.

    

    All
      the
      representations, covenants, warranties, undertakings, remedies, indemnification,
      and other rights including but not limited to reservation requirements and
      registration rights made or granted to or for the benefit of the Purchasers
      are
      hereby also made and granted to and for the benefit of the Investment Banker
      in
      respect of the Investment Banker’s Shares.BLSM form 10QSB 04-30-2006 EX.3

    STOCK
      PURCHASE AGREEMENT

    

    This
      STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of the
      2nd
      day of
      June, 2006, by and between Bio Solutions Manufacturing, Inc., a New York
      corporation (“Issuer”), and Bio Solutions Franchise Corp. a Florida corporation
      (“BSFC”). The Issuer and BSFC shall each sometimes be referred to as a “Party”
and collectively as the “Parties.”

    

    In
      consideration of the mutual promises, covenants, and representations contained
      herein, and other good and valuable consideration,

    

    THE
      PARTIES HERETO AGREE AS FOLLOWS:

    

    
      	
              1.

            	
              EXCHANGE
                OF SECURITIES.
                Subject to the terms and conditions of this agreement, the Issuer
                agrees
                to issue to BSFC an aggregate of Ten Million (10,000,000) shares
                of the
                common stock of the Issuer, par value $0.001 per share (the “Issuer
                Shares”), in exchange for 100% of the issued and outstanding shares of Bio
                Extraction Services, Inc. (“BESI”), such that BESI shall become a
                wholly-owned subsidiary of the Issuer.

            

    

    

    
      	
              2.

            	
              REPRESENTATIONS
                AND WARRANTIES OF ISSUER.
                Issuer represents and warrants, to the best of their knowledge, to
                BSFC
                the following:

            

    

    

    
      	
               

            	
              i.
                

            	
              Organization.
                Issuer is a corporation duly organized, validly existing, and in
                good
                standing under the laws of the State of New York, and has all necessary
                corporate powers to own properties and carry on its business, and
                is duly
                qualified to do business and is in good standing in the State of
                New York
                and the State of Mississippi.

            

    

    

    
      	 	
              ii.

            	
              Capital.
                The authorized capital stock of Issuer consists of One Hundred Million
                (100,000,000) shares of common stock, par value $0.001 per share,
                of which
                approximately Twenty Five million shares are issued and outstanding
                (25,000,000) shares are issued and outstanding, and Ten Million
                (10,000,000) shares of preferred stock, par value $0.001 per share,
                none
                of which are issued or outstanding. All outstanding shares are fully
                paid
                and non-assessable, and are free of liens, encumbrances, options,
                restrictions and legal or equitable rights of others not a party
                to this
                Agreement. 

            

    

    

    
      	 	
              iii.

            	
              Financial
                Statements.
                Exhibit A to this Agreement includes the current balance sheet of
                Issuer,
                and the related statements of income and retained earnings as of
                and for
                the fiscal year ended October 31, 2005 (the “Financial Statements”). The
                Financial Statements have been prepared in accordance with generally
                accepted accounting principles consistently followed by Issuer throughout
                the periods indicated, and fairly present the financial position
                of Issuer
                as of the date of the balance sheet and the Financial Statements,
                and the
                results of its operations for the periods
                indicated.

            

    

    

    
      
        1

        

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	
              iv.

            	
              Absence
                of Changes.
                Since the date of the Financial Statements, there has not been any
                change
                in the financial condition or operations of Issuer, except changes
                in the
                ordinary course of business, which changes have not in the aggregate
                been
                materially adverse.

            

    

    

    
      	 	
              v.
                

            	
              Ability
                to Carry Out Obligations.
                Issuer has the right, power, and authority to enter into and perform
                its
                obligations under this Agreement. The execution and delivery of this
                Agreement by Issuer and the performance by Issuer of its obligations
                hereunder will not cause, constitute, or conflict with or result
                in (a)
                any breach or violation or any of the provisions of or constitute
                a
                default under any license, indenture, mortgage, charter, instrument,
                articles of incorporation, bylaw, or other agreement or instrument
                to
                which Issuer or its shareholders are a party, or by which they may
                be
                bound, nor will any consents or authorizations of any party other
                than
                those hereto be required, (b) an event that would cause Issuer to
                be
                liable to any party, or (c) an event that would result in the creation
                or
                imposition or any lien, charge or encumbrance on any asset of Issuer
                or
                upon the securities of Issuer to be acquired by BSFC.
                

            

    

    

    
      	 	
              vi.

            	
              Compliance
                with Laws.
                Issuer has complied with and is not in violation of any federal,
                state, or
                local statute, law, and/or regulation pertaining to Issuer. Issuer
                has
                complied with all federal and state securities laws in connection
                with the
                issuance, sale and distribution of its securities.
                

            

    

    

    
      	 	
              vii.

            	
               Litigation.
                Issuer is not a party to any suit, action, arbitration, or legal,
                administrative or other proceeding, or pending governmental investigation.
                There is no basis for any such action or proceeding and no such action
                or
                proceeding is threatened against Issuer and Issuer is not subject
                to or in
                default with respect to any order, writ, injunction, or decree of
                any
                federal, state, local, or foreign court, department, agency, or
                instrumentality.

            

    

    

    
      	 	
              viii.
                

            	
              Absence
                of Certain Changes.
                Except as set forth in Exhibit B attached hereto, or as specifically
                contemplated in this Agreement, since April 30, 2006, the Issuer
                and its
                subsidiaries have not:

            

    

    

    
      	 	
              (1)
                

            	
              suffered
                any material adverse change in its working capital, financial condition,
                assets, liabilities, business, or prospects, or suffered any material
                casualty loss (whether or not
                insured);

            

    

    

    
      	 	
              (2)
                

            	
              made
                any change in business operations or in the manner of conducting
                business
                inconsistent with past practice;

            

    

    

    
      	 	
              (3)
                

            	
              paid,
                discharged or satisfied any claim, lien, encumbrance or liability
                other
                than in the ordinary course of business and consistent with past
                practice;

            

    

    

    
      	 	
              (4)
                

            	
              other
                than in the ordinary course of its business, paid, made, or set aside
                for
                payment any distribution in respect of its shareholders or directly
                or
                indirectly redeemed, purchased or otherwise acquired any shares of
                its
                capital stock;

            

    

    

    
      	 	
              (5)
                

            	
              made
                any change in any method of accounting or accounting
                practice.

            

    

    

    
      	 	
              ix.

            	
              Material
                Contracts.
                All material contracts, agreements, commitments, and instruments
                to which
                the Issuer and/or any of its subsidiaries are subject and by which
                they
                are bound are listed in Exhibit C and true and correct copies thereof
                have
                been provided to BSFC. All such contracts are in full force and effect,
                there have been no cancellations thereof, there are no outstanding
                disputes there under, and there does not exist any default in any
                material
                respect, or event, which is a breach in any material respect, of
                the terms
                of such contract. 

            

    

    

    
      	 	
              x.

            	
              Tax
                Returns. Issuer
                and all of its subsidiaries have filed, with appropriate governmental
                authorities, all tax and related returns required to be filed, and
                such
                returns adequately reflect all taxes payable, copies of which shall
                be
                provided upon the signing of this Agreement.

            

    

    

    
      	 	
              xi.
                

            	
              Title.
                The Issuer Shares at Closing will be free and clear of all liens,
                security
                interests, pledges, charges, claims, encumbrances and restrictions
                of any
                kind except as imposed under the terms of this Agreement and under
                federal
                and applicable state securities laws, and all such shares shall bear
                the
                restrictive legend in Section 3.B.i.(2) below. None of the Issuer
                Shares
                or BSLM Shares are or will be subject to any voting trust or agreement.
                No
                person holds or has the right to receive any proxy or similar instrument
                with respect to such shares, and, except as provided in this Agreement,
                the Issuer is not a party to any agreement that offers or grants
                to any
                person the right to purchase or acquire any of the Issuer Shares.
                There is
                no applicable local, state or federal law, rule, regulation, or decree,
                that Issuer is currently aware of, which would, as a result of the
                issuance of the Issuer Shares to BSFC, impair, restrict or delay
                BSFC's
                voting rights with respect to the Issuer Shares.
                

            

    

    
      	 	
              xii.
                

            	
              Insurance.
                Neither the Issuer nor any of its subsidiaries are insureds under
                any
                insurance policies. 

            

    

    

    
      	 	
              xiii.
                

            	
              Brokers,
                Finders.
                No agent, broker, investment banker, person, or firm acting on behalf
                of
                the Issuer or any of its subsidiaries is or will be entitled to any
                broker’s or finder’s fee or any other commission or similar fee directly
                or indirectly in connection with the transactions contemplated hereby.
                

            

    

    

    
      	 	
              xiv.

            	
              Disclosure.
                Neither this Agreement nor any schedule, exhibit, list, certificate
                or
                other instrument or document delivered to BSFC pursuant to this Agreement
                by or on behalf of the Issuer or any of its subsidiaries, contains
                any
                untrue statement of a material fact or omits to state any material
                fact
                required to be stated herein or therein to make the statements,
                representations or warranties and information contained herein or
                therein
                not misleading. 

            

    

    

    3. REPRESENTATIONS
      AND WARRANTIES OF BSFC.

    

    A. BSFC
      represents and warrants, to the best of its knowledge, to the Issuer the
      following:

    

    
      	 	
              i.
                

            	
              Organization.
                BSFC is a corporation duly organized, validly existing, and in good
                standing under the laws of Florida, has all necessary corporate powers
                to
                own properties and carry on a business, and is duly qualified to
                do
                business and is in good standing in
                Florida.

            

    

    

    
      	 	
              ii.

            	
              Litigation.
                BSFC is not a party to any suit, action, arbitration, or legal,
                administrative, or other proceeding or pending governmental investigation.
                To the best knowledge of BSFC, there is no basis for any such action
                or
                proceeding and no such action or proceeding is threatened against
                BSFC and
                BSFC is not subject to or in default with respect to any order, writ,
                injunction, or decree of any federal, state, local, or foreign court,
                department, agency, or
                instrumentality.

            

    

    

    
      	 	
              iv.

            	
              Tax
                Returns.
                BSFC and all of its subsidiaries have filed, with appropriate governmental
                authorities, all tax and related returns required to be filed, and
                such
                returns adequately reflect all taxes payable. All federal, state,
                local,
                county, franchise, sales, use, excise, property, and other taxes
                payable
                have been paid, and no reserves for unpaid taxes have been set up
                or are
                required.

            

    

    

    
      	 	
              v.

            	
              Ability
                to Carry Out Obligations.
                BSFC has the right, power, and authority to enter into and perform
                its
                obligations under this Agreement. The execution and delivery of this
                Agreement by BSFC and the performance by BSFC of its obligations
                hereunder
                will not cause, constitute, of conflict with or result in (a) any
                breach
                or violation or any of the provisions of or constitute a default
                under any
                license, indenture, mortgage, charter, instrument, articles of
                incorporation, bylaw, or other agreement or instrument to which BSFC
                or
                its shareholders are a party, or by which they may be bound, nor
                will any
                consents or authorizations of any party other than those hereto be
                required, (b) an event that would cause BSFC to be liable to any
                party, or
                (c) an event that would result in the creation or imposition or any
                lien,
                charge or encumbrance on any asset of BSFC or upon the BSFC
                Shares.

            

    

    

    
      	 	
              vi

            	
              Material
                Contracts.
                All material contracts, agreements, commitments, and instruments
                to which
                BSFC is subject and by which it is bound are in full force and effect,
                there have been no cancellations thereof, there are no outstanding
                disputes there under, and there does not exist any default in any
                material
                respect or event, which is a breach in any material respect of the
                terms
                of such contract, commitments and instruments.

            

    

    

    
      
        1

        

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	
              vii

            	
              Brokers,
                Finders.
                No agent, broker, investment banker, person, or firm acting on behalf
                BSFC
                is or will be entitled to any broker’s or finder’s fee or any other
                commission or similar fee directly or indirectly in connection with
                the
                transactions contemplated hereby.

            

    

    

    B. BSFC
      represents and warrants, to the best of its knowledge, to the Issuer the
      following:

    

    i.
       Securities
      Law Matters.

    

    
      	(1)  	
              BSFC
                is acquiring the Issuer Shares for their own account for investment
                only
                and not with a view towards, or in connection with, the public sale
                or
                distribution thereof, except pursuant to sales registered, or exempt
                from
                registration, under the Securities Act of 1933 (the “1933 Act”) and
                applicable state securities laws. BSFC shall offer, sell, pledge,
                hypothecate or otherwise transfer the Issuer Shares except pursuant
                to
                registration under the 1933 Act and applicable state securities laws
                or an
                exemption from registration under the 1933 Act and any applicable
                state
                securities laws. BSFC (i) has such knowledge and experience in financial
                and business matters that it is capable of evaluating the merits
                and risks
                of an investment in the Issuer and (ii) is aware that an investment
                in the
                Issuer Shares involves a high degree of risk and that they may be
                required
                to bear such risk for an indefinite period of time, and that they
                are able
                to bear such risk. BSFC understands that the Issuer Shares are being
                offered and exchanged in reliance on specific exemptions from the
                registration requirements of federal and applicable state securities
                laws,
                and that the Issuer is relying upon the truth and accuracy of, and
                BSFC’s
                compliance with, their representations, warranties and agreements
                herein
                in order to determine the availability of such exemptions and the
                eligibility of BSFC to acquire the Issuer Shares. BSFC has been (i)
                furnished with all materials relating to the business, finances and
                operations of the Issuer and the offer and exchange of the Issuer
                Shares
                that they have requested and (ii) afforded the opportunity to ask
                all
                questions of the Issuer as they have in their discretion deemed advisable.
                BSFC has sought such accounting, legal and tax advice, as they have
                considered necessary to make an informed investment decision with
                respect
                to their acquisition of the Issuer
                Shares.

            

    

    

    
      	 	
              (2)
                

            	
              BSFC
                understands that the stock certificates and documents representing
                the
                Issuer Shares will bear a restrictive legend in substantially the
                following form:

            

    

    

    THE
      SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
      OF
      1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS (COLLECTIVELY,
      THE “LAWS”). THE SHARES MAY NOT BE OFFERED FOR SALE, SOLD, OR OTHERWISE
      TRANSFERRED IN THE ABSENCE OF EITHER (I) AN EFFECTIVE REGISTRATION STATEMENT
      FOR
      THE SECURITIES UNDER THE LAWS OR (II) AN OPINION OF COUNSEL PROVIDED TO THE
      ISSUER IN FORM, SUBSTANCE AND SCOPE REASONABLY ACCEPTABLE TO THE ISSUER TO
      THE
      EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER THE LAWS DUE TO AN AVAILABLE
      EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE LAWS.

    

    
      	 	
              ii

            	
              Title.
                The BSFC Shares will be, at Closing, free and clear of all liens,
                security
                interests, pledges, charges, claims, encumbrances and restrictions
                of any
                kind except as imposed under federal and applicable state securities
                laws,
                and all such shares shall bear an appropriate restrictive legend.
                None of
                the BSFC Shares are or will be subject to any voting trust or agreement.
                No person holds or has the right to receive any proxy or similar
                instrument with respect to such shares and BSFC is not a party to
                any
                agreement that offers or grants to any person the right to purchase
                or
                acquire any of the BSFC Shares. There is no applicable local, state
                or
                federal law, rule, regulation, or decree which would, as a result
                of the
                delivery of the BSFC Shares to the Issuer, impair, restrict or delay
                Issuer’s voting rights with respect to the BSFC
                Shares.

            

    

    

    
      	
              5.

            	
              DATE
                AND TIME OF CLOSING.
                The closing of the transactions described herein (the “Closing”), shall
                take place at the offices of BSFC on June 1, 2006, or at such other
                place,
                date and time as the Parties may agree in writing (the “Closing Date”).
                

            

    

    

    6. DOCUMENTS
      TO BE DELIVERED AT CLOSING.

    

    i.
       By
      the Issuer.

    

    
      	(1)  	
              Board
                of Directors Minutes authorizing the issuance of the Issuer Shares
                in the
                name of BSFC.

            

    

     

    
      	 	
              (2)

            	
              Delivery
                to BSFC of the Ten Million BSLM Shares in the name of BSFC.
                

            

    

    

    (3) A
      copy of
      this Agreement signed by authorized officer(s) of BSLM.

    

    ii.
       By
      BSFC.

    

    
      	 	
              (1)
                

            	
              Delivery
                to the Issuer of certificates representing the BESI Shares, together
                with
                validly executed stock powers containing applicable Medallion signature
                guarantees.

            

    

    

    
      	(2)  	
              A
                copy of this Agreement signed by
                BSFC.

            

    

    

    
      	
              7.

            	
              REMEDIES.
                Any controversy or claim arising out of, or relating to, this Agreement,
                or the making, performance, or interpretation thereof, shall be settled
                by
                arbitration in Hattiesburg, Mississippi in accordance with the Rules
                of
                the American Arbitration Association then existing, and judgment
                on the
                arbitration award may be entered in any court having jurisdiction
                over the
                subject matter of the controversy. The rules of discovery for the
                arbitration shall be determined by the Parties or by the arbitrator
                if the
                Parties cannot agree.

            

    

    

    8. INDEMNIFICATION.

    

    
      	 	
              i.
                

            	
              Indemnification
                by the Issuer.
                The Issuer shall indemnify, hold harmless, and reimburse BSFC and
                its
                shareholders, officers and directors from and against any and all
                claims,
                losses, damages, liabilities, diminution of value and costs and related
                expenses (including without limitation, settlement costs and any
                legal or
                other fees or expenses for investigating or defending any actions
                or
                threatened actions), whether or not involving a third party claim,
                reasonably incurred by BSFC in connection with any of the
                following:

            

    

    

    
      	(1)  	
              any
                misrepresentation or breach of any warranty made by the Issuer or
                any of
                its subsidiaries under this Agreement as to which a notice is given
                under
                paragraph iii. Below within the time period specified in Section
                9.ix.
                below; and

            

    

    

    
      	(2)  	
              the
                non-fulfillment or breach of any covenant, agreement, or obligation
                of the
                Issuer or any of its subsidiaries contained in or contemplated by
                this
                Agreement that occurs prior to the
                Closing.

            

    

    

    
      	 	
              ii.

            	
              Indemnification
                by BSFC.
                BSFC shall
                indemnify, hold harmless, and reimburse the Issuer from and against
                any
                and all claims, losses, damages, liabilities, diminution of value
                and
                costs and related expenses (including without limitation, settlement
                costs
                and any legal or other fees or expenses for investigating or defending
                any
                actions or threatened actions), whether or not involving a third
                party
                claim, reasonably incurred by the Issuer in connection with any of
                the
                following: 

            

    

    

    
      	 	
              (1)
                

            	
              any
                misrepresentation or breach of any warranty made by BSFC under this
                Agreement as to which a notice is given under paragraph iii. below
                within
                the time period specified in Section 9.vii. below;
                

            

    

    

    
      	 	
              (2)
                

            	
              the
                non-fulfillment or breach of any covenant, agreement, or obligation
                of
                BSFC or the BSFC Shareholders contained in or contemplated by this
                Agreement; and 

            

    

    

    
      	 	
              (3)
                

            	
              any
                obligation related to or arising from the business of BSFC either
                before
                or after the Closing.

            

    

    

    
      	 	
              iii.
                

            	
              Procedure
                for Indemnity.
                The indemnified parties shall promptly notify the Indemnifying party
                of
                any claim, demand, action or proceeding (collectively, a “Claim”) for
                which indemnification will be sought under this Section 8,
                and if such Claim is a third party Claim, the indemnifying party
                will have
                the right, at its expense, to assume the defense thereof using counsel
                reasonably acceptable to the indemnified party. The indemnified party
                shall have the right to participate, at its own expense, with respect
                to
                any such third party Claim. In connection with any such third party
                Claim,
                the parties hereto shall cooperate with each other and provide each
                other
                with access to relevant books and records in their possession. No
                such
                third party Claim shall be settled without the prior written consent
                of
                the indemnified party, which consent shall not be unreasonably withheld.
                If a firm written offer is made to settle any such third party Claim
                and
                the indemnifying party proposes to accept such settlement and the
                indemnified party refuses to consent to such settlement, then: (i)
                the
                indemnifying party shall be solely responsible for, all further defense
                of
                such third party Claim; and (ii) the maximum liability of the indemnifying
                party relating to such third party Claim shall be the amount of the
                proposed settlement if the amount thereafter recovered from the
                indemnified party on such third party Claim is greater than the amount
                of
                the proposed settlement.

            

    

    

    9. MISCELLANEOUS.

    

    
      	 	
              i.

            	
              Captions
                and Headings.
                The Article and Section headings throughout this Agreement are for
                convenience and reference only, and shall in no way be deemed to
                define,
                limit, or add to the meaning of any provision of this
                Agreement.

            

    

    

    
      	 	
              ii.

            	
              No
                Oral Changes.
                This Agreement and any provision hereof may not be changed, modified,
                or
                discharged orally, but only by an agreement in writing signed by
                the Party
                against whom enforcement of any change, modification, or discharge
                is
                sought.

            

    

    

    
      	 	
              iii.

            	
              Non-Waiver.
                No waiver of any covenant, condition, or provision of this Agreement
                shall
                be deemed to have been made unless expressly in writing and signed
                by the
                Party against whom such waiver is charged; and (i) the failure of
                any
                Party to insist in any one or more cases upon the performance of
                any of
                the provisions, covenants, or conditions of this Agreement or to
                exercise
                any option herein contained shall not be construed as a waiver or
                relinquishment for the future of any such provisions, covenants,
                or
                conditions, (ii) the acceptance of performance of anything required
                by
                this Agreement to be performed with knowledge of the breach or failure
                of
                a covenant, condition, or provision hereof shall not be deemed a
                waiver of
                such breach or failure, and (iii) no waiver by any Party of one breach
                by
                another Party shall be construed as a waiver with respect to any
                other or
                subsequent breach.

            

    

    

    
      	 	
              iv.
                

            	
              Time
                of Essence.
                Time is of the essence for this Agreement and of each and every provision
                hereof.

            

    

    

    
      	v.  	
              Entire
                Agreement.
                This Agreement, with exhibits, contains the entire Agreement and
                understanding between the Parties hereto, and supersedes all prior
                agreements and understandings whether oral or in
                writing.

            

    

    

    
      
        1

        

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	
              vi.

            	
              Counterparts.
                This Agreement may be executed simultaneously in one or more counterparts,
                each of which shall be deemed an original, but all of which together
                shall
                constitute one and the same
                instrument.

            

    

    

    
      	 	
              vii.

            	
              Notices.
                All notices, requests, demands, and other communications under this
                Agreement shall be in writing and shall be deemed to have been duly
                given
                on the date of service if served personally on the Party to whom
                notice is
                to be given, or on the third day after mailing if mailed to the Party
                to
                whom notice is to be given, by first class mail, registered or certified,
                postage prepaid, and properly addressed as
                follows:

            

    

    

    Issuer:  Bio
      Solutions Franchise Corp.

    1161
      James Street

    Hattiesburg,
      MS 39401 

    

    BSFC:  Bio
      Solutions Manufacturing, Inc.

    1161
      James Street

    Hattiesburg,
      MS 39401 

    

    
      	 	
              viii.

            	
               Attorney’s
                Fees.
                Except as otherwise provided herein, if a dispute should arise between
                the
                Parties including, but not limited to, arbitration, the prevailing
                Party
                shall be reimbursed by the non-prevailing Party for all reasonable
                expenses incurred in resolving such dispute, including reasonable
                attorneys' fees, exclusive of such amount of attorneys' fees as shall
                be a
                premium for result or for risk of loss under a contingency fee
                arrangement.

            

    

    

    
      	 	
              ix.
                

            	
              Survival
                of Representations.
                The representations and warranties given hereunder shall survive
                for a
                period of one (1) year following the Closing Date.
                

            

    

    

    
      	 	
              x.
                

            	
              Governing
                Law.
                It is the intention of the Parties that the law of the State of
                Mississippi should govern the validity of this Agreement, the construction
                of its terms and the interpretation of the rights and duties of the
                Parties, without regard to the conflict of laws rules
                thereof.

            

    

    

    
      	 	
              xi.
                

            	
              Successors
                and Assigns.
                This Agreement shall be binding upon the Parties, and their heirs,
                legal
                representatives, successors and
                assigns.

            

    

    

    
      	 	
              xii.

            	
              Authority
                of Corporate Signatories.
                Each individual signing on behalf of a Party, not a natural person,
                that
                is an entity has the authority to execute this Agreement on behalf
                of such
                person.

            

    

    

    
      	 	
              xiii.
                

            	
              No
                Interpretation Against Drafter.
                This Agreement has been negotiated at arms’- length between persons
                sophisticated and knowledgeable in these types of matters. Accordingly,
                any normal rules of construction that would require a court to resolve
                matters of ambiguities against the drafting party is hereby waived
                and
                shall not apply in interpreting this
                Agreement.

            

    

    

    
      	 	
              xiv.

            	
              Costs
                and Expenses.
                Except as provided in Sections 2.v., 2.viii., 7 and 8 above, all
                expenses
                (including attorney’s and accountant’s fees) incurred by any Party in
                connection with (i) the preparation and negotiation of this Agreement
                and
                the other agreements and documents referred to herein and (ii) the
                consummation of the transactions referred to herein or therein (whether
                occurring prior to or after the Closing), shall be borne by the Party
                who
                incurred them. 

            

    

    

    

    IN
      WITNESS WHEREOF,
      the
      undersigned have duly executed this Agreement on the date first written
      above.

    

    

    BIO
      SOLUTIONS FRANCHISE CORP.

    

    

    

    By:      

    N.
      Wayne
      Wade, President

    

    

    BIO
      SOLUTIONS MANUFACTURING, INC.

    

    

    

    By:      

    David
      Bennett, President

    

    
      
        1

        

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    EXHIBIT
      A

    

    Issuer’s
      Financial Statements as of June 30, 2004.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]